Arrowhead Pharma Stock Price, News & Analysis

Takeda (TSE:4502/NYSE:TAK) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) announced positive results from the Phase 2 SEQUOIA study for fazirsiran in treating liver disease due to alpha-1 antitrypsin deficiency (AATD-LD). Notable findings include a 50% fibrosis regression in patients and a 94% median reduction in liver Z-AAT accumulation. Adverse events were balanced between treatment and placebo groups. A Phase 3 study is set to begin this month, aiming to confirm these promising Phase 2 results.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 11:15 a.m. ET in San Francisco. This event is a significant platform for healthcare companies to discuss innovations and business strategies.

A webcast of the presentation will be accessible on the Arrowhead Pharmaceuticals website under the Investors section.

Arrowhead Pharmaceuticals (ARWR) announced it will present topline data from its SEQUOIA Phase 2 study of fazirsiran on January 9, 2023, at 8:30 a.m. ET. This investigational RNA interference therapy aims to treat alpha-1 antitrypsin deficiency, a rare genetic liver disease. The Phase 3 study will be co-developed with Takeda. AAT deficiency affects 1 in 3,000-5,000 individuals in the U.S. Arrowhead and Takeda's collaboration includes a profit-sharing structure and potential milestone payments exceeding $1 billion.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced a $25 million milestone payment from Amgen (NASDAQ: AMGN) triggered by the enrollment of the first subject in Amgen's Phase 3 trial of olpasiran. Arrowhead is also in line to receive up to $535 million in additional milestone payments from Amgen and Royalty Pharma (NASDAQ: RPRX). The olpasiran therapy targets lipoprotein(a) to reduce cardiovascular disease risk. This milestone represents significant progress for Arrowhead, being the second TRiM-enabled candidate to enter Phase 3 trials, with more projected to follow in the coming year.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced on December 9, 2022 the approval of inducement grants for 35 new employees, totaling up to 84,000 restricted stock units. These grants, approved by the Compensation Committee, are issued outside of the company’s stockholder-approved equity incentive plans and will vest annually over four years. Arrowhead develops innovative therapies for intractable diseases through RNA interference, targeting the genes responsible for these conditions.

Horizon Therapeutics plc (Nasdaq: HZNP) announced the dosing of the first subject in a Phase 1 clinical trial for HZN-457, a small interfering RNA designed to treat gout by silencing liver xanthine dehydrogenase. This trial aims to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in up to 56 healthy volunteers. Gout affects over 9 million patients in the U.S., with many inadequately treated by current therapies. HZN-457 aims to lower uric acid levels effectively, potentially improving patient outcomes. The development is part of a collaboration with Arrowhead Pharmaceuticals (Nasdaq: ARWR).

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has received a $15 million milestone payment from Horizon Therapeutics (NASDAQ: HZNP) following the enrollment of the first subject in a Phase 1 clinical trial for HZN-457, aimed at treating gout. This candidate, previously known as ARO-XDH, targets liver xanthine dehydrogenase to lower uric acid levels. The study will enroll 56 healthy volunteers to assess safety, tolerability, and pharmacokinetics. The collaboration with Horizon is pivotal in advancing innovative treatments for the over 9 million gout patients in the U.S.

Arrowhead Pharmaceuticals reported fiscal year 2022 results, achieving $243.2 million in revenue, up from $138.3 million in 2021. The company incurred a net loss of $172.7 million or $1.67 per diluted share. Operating expenses rose to $421.7 million compared to $287.3 million the prior year. Despite financial challenges, significant progress was made in clinical trials, with promising interim data on ARO-APOC3 and ARO-ANG3. The balance sheet was bolstered by a $250 million royalty sale and potential future earnings from Amgen.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) will hold a webcast and conference call on November 28, 2022, at 4:30 p.m. ET to discuss its financial results for the fiscal year ending September 30, 2022. Investors can access the live audio via the company’s website, with a replay available two hours post-call. Arrowhead focuses on developing RNA interference therapies targeting intractable diseases.